Regeneron buys Checkmate Pharmaceuticals for $250M cash

Regeneron plans to show there is more to skin cancer tha | Regeneron has shown there is more to skin cancer drugs than PD-1 inhibitors through its $250 million acquisition of Checkmate Pharmaceuticals and its lead immuno-oncology asset vidutolimod.

Regeneron to Acquire Checkmate for $250M, Expanding Cancer I/O Pipeline

Regeneron signs agreement to acquire Checkmate for $250m

Regeneron HealthCare Middle East & Africa Magazine

Page 137 – BioProcess InternationalBioProcess International, Covering the whole development process for the global biotechnology industry

Regeneron Stock: Fortune Seems To Favor This Bold, Innovative Pharma (NASDAQ:REGN)

I Bytes Healthcare industry

Life Sciences Co. Expected to Attract Partners Big Pharma

Regeneron Stock: Fortune Seems To Favor This Bold, Innovative Pharma (NASDAQ:REGN)

Cancer Therapeutics Via IPO 2020-2022 - Dennis Gong

Regeneron to Acquire Checkmate Pharmaceuticals for $250M